Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry today announced that Kristin Arnold, Ph.D. has joined the company as vice president, product development and technical services (PDTS). Arnold will provide strategic leadership for Norwich’s PDTS group that includes R&D, GMP pilot scale manufacturing, analytical development and validation, and testing services. Arnold will report to Chief Executive Officer Doug Drysdale.
"We are pleased to welcome Kristin Arnold to Norwich and look forward to her contributions to the PDTS group and the organization," stated Drysdale. "Her expertise in product development from product conception through market launch will be an advantage for our customers and she will be a strong addition to our leadership team."
Prior to joining Norwich, Dr. Arnold worked for organizations including URL Pharma as Sr. Vice President Product Development, Alpharma (formerly Faulding Pharmaceutical Company) as Sr. Director Research and Development, FMC Corporation, Ecogen, and Monsanto.
Dr. Arnold holds a Bachelor of Science in chemistry from LaSalle University and a Ph.D. in organic chemistry from the University of Miami. She is a member of both the American Chemical Society and the...
Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has been recognized as Manufacturer of the Year by the Chenango County Chamber of Commerce. The award presentation occurs at a time when Norwich is celebrating 125 years of continuous operation for pharmaceutical manufacturing.
“The Chamber recognizes that managing a manufacturing business in a rural environment can be challenging,” said Steve Craig, president and CEO of the Chenango Chamber. “The continued success and sustainability shown by Norwich Pharmaceuticals indicates an ability to respond to changing market demands and contribute to our local economy.”
Selection criteria for the award included employment growth, increase in sales, contributions to the community, and current and past financial results. Previous award winners include The Mid-York Press, Chentronics Corporation, and Sunrise Family Farms.
“Norwich is honored to receive this important recognition from Commerce Chenango and the member companies of the Chamber,” said Terry Novak, president of Norwich. “We constantly are focused to ensure that the life-saving medications we produce meet high quality standards for our customers, for patients, and also for our local...
Norwich Pharmaceuticals has been recognized by the American Heart Association as a 2012 Fit-Friendly Worksite. Norwich achieved gold-level status for promoting physical activity and health in the workplace. Fit-Friendly Worksites reach gold-level status by implementing various programs to encourage physical activity, nutrition and culture enhancements, such as on-site walking routes, healthy food choices in cafeterias and vending machines, annual employee health risk assessments and online tracking tools.
American employers face increasing healthcare expenses and health-related losses in productivity that cost an estimated $225.8 billion a year. Many American adults spend most of their waking hours at sedentary jobs. Their lack of regular physical activity raises their risk for a host of medical problems, such as obesity, high blood pressure and diabetes. Employers face $12.7 billion in annual medical expenses due to obesity alone. The American Heart Association Fit-Friendly recognition helps to change corporate cultures by motivating employees to start walking, which has the lowest dropout rate of any physical...
In the November issue of International Clinical Trials magazine, Norwich Pharmaceuticals discusses its approach to pharmacovigilance in the expanding global environment.
Terry Novak, President, Norwich Pharmaceuticals talks with Mike Auerbach, Editor In Chief, Pharmaceutical Processing about Norwich, the services it provides to the pharmaceutical industry as well as his opinion on pharmaceutical outsourcing.
Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today that the company has achieved significant business growth in first quarter, 2012 as compared to the same period in 2011. Key growth areas include volume of projects currently in development and commercial production, scope of projects expanded into multiple service categories, and total value of new business won.
"Norwich's growth is a direct result of our ability to maintain high quality standards while providing expertise and flexibility for both product development and commercial manufacturing," said Terry Novak, president of Norwich. "During the past year, Norwich has expanded our capabilities to meet the market demands for smaller scale development services. Providing expertise in novel, solid dose formulations, we have been able to offer services to new clientele while increasing our repeat business rate with current customers."
New client awards in the first quarter accounted for 33% of all Norwich projects while repeat business in Q1, 2012 more than doubled as compared to the same period last year. The total value of new projects increased 25%. Several of the new projects will utilize Norwich services for potent compounds, low humidity, bead extrusion, tablet coating,...
In the January/February issue of Pharmaceutical Processing magazine, Norwich Pharmaceuticals is featured as a company that can "do it all" among contract development and manufacturing organizations.
Growing market demand leads to expansion at two research facilities
Norwich, New York – February 2, 2012 – Norwich Clinical Services (NCS), a global provider of clinical research services for the pharmaceutical and biotech industries, today announced a significant expansion to its clinical research capabilities in order to meet growing market demand. Primary to the expansion, NCS unveiled a new clinical facility with capabilities to conduct all aspects of Phase I – III clinical trials including pharmacokinetics in healthy volunteers, bio-availability and bio-equivalence studies, drug metabolism studies, dose proportionality studies and multiple dose studies.
"Utilizing proven technologies and this new, modern clinical facility, NCS is now able to offer functional expertise and therapeutic experience with reliability that will create cost and time efficiency for customers," stated Dr. Saral Thangam, MD, PhD, managing director of Norwich Clinical Services. "We are proud to be opening this new clinical trial facility with full regulatory approval from the Drugs Controller General of India as an indication of our unequivocal adherence to GCP, GLP, CFR part 11 and other applicable regulatory requirements."
The 72-bed, 16,500 square foot facility has been successfully audited by the Drugs...
Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing for the pharmaceutical and biotech industry, announced today that the company has been awarded $2 million by the State of New York Regional Economic Development Council. Norwich received the award based on the endorsement of the local Regional Council and the technical scoring of various state funding agencies.
“Norwich Pharmaceuticals is appreciative for the funding provided by the Governor’s Office and the Regional Economic Development Council,” said Terry Novak, president of Norwich Pharmaceuticals. “Community partnership has performed a critical role throughout the nearly 125 year history of Norwich Pharmaceuticals, and this funding will support our current efforts to expand capabilities and drive additional business into the Southern Tier.”
Funding received through the Regional Council will be applied to an expansion that includes equipment, surface area and staff. Once completed in 2012, the expansion will more than double Norwich Pharmaceuticals’ current capacity for pilot scale development and manufacturing.
Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing for the pharmaceutical and biotech industry, announced today that new business partnerships secured during the fourth quarter will generate significant revenue for the company. Norwich has been expanding its development and pilot scale capabilities throughout 2011 in order to meet the growing market demand for comprehensive solutions that include scale-up and commercial manufacturing.
“Norwich is intensely focused to provide an experience for our customers that improves time efficiency and ensures quality,” said Terry Novak, president of Norwich Pharmaceuticals. “We continue to strategically invest in unique technical capabilities, and our strength with global distribution is being recognized as an advantage for several new customers.”
The new business partnerships announced today include five new projects that could add more than 500 million units to Norwich commercial production during the next three years with finished product being distributed in both the U.S. and Europe.
Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing for the pharmaceutical and biotech industry, today announced the increase of its pilot scale production capabilities, including a facility expansion that doubles current capacity for pilot scale development and manufacturing. The additions at the Norwich, New York facility include equipment, surface area and staff.
“We’re providing a world class experience for customers seeking product development and pilot scale manufacturing services,” said Terry Novak, president of Norwich Pharmaceuticals. “Through this significant capital investment, Norwich is not only adding production capacity, we also are strengthening project management, increasing on-time delivery and further expanding our capability to provide customers with one comprehensive solution for all stages of the product lifecycle.”
Norwich development and pilot scale facilities comprise 12,000 square feet of dedicated space with DEA, solvent and potent compound capabilities including two analytical laboratories dedicated to support R&D and GMP development projects. The facilities, instrumentation and technology mirror Norwich commercial capabilities, thus allowing direct transfer from analytical services to quality control and enabling a fast track to trade production.
...
Norwich Pharmaceuticals today announced that Terence Novak has joined the company as president, Commercial Operations. Novak will provide strategic leadership for Norwich Pharmaceuticals' commercial business group that includes sales, marketing and customer service. Novak will report to Chief Executive Officer Doug Drysdale.
"We are pleased to welcome Terry Novak to Norwich and look forward to his results-oriented approach to business development and customer service," stated Drysdale. "His expertise within the contract services industry complemented by his energetic commitment to customers will be a strong addition to our leadership team."
Novak was most recently president and chief commercial officer for Patheon, Inc., where he successfully achieved an increase in new business while also overseeing five manufacturing facilities. Prior to this role, Novak held several senior leadership positions at DSM Pharmaceuticals including senior vice president commercial operations; executive vice president and chief marketing officer; and president and business unit director. Novak also possesses more than fifteen years sales and management experience with Bristol Myers Squibb. He holds a Bachelor of Science in biology from Muhlenberg College.
Norwich, a leader in full-service contract development and manufacturing, is expanding its services to now include small scale feasibility and initial product development for prescription and over-the-counter pharmaceuticals. The non-GMP development facility will offer Norwich customers greater flexibility and speed when assessing the feasibility of technical concepts and formulations, and create streamlined progression from clinical into scale-up and through commercial manufacturing.
Norwich's comprehensive product development capabilities include formulation, analytical method development and validation, process optimization, and scalable manufacturing. The state-of-the-art, non-GMP facility is comprised of an analytical laboratory designed for potent compound handling, and a development area enabling formulation and product transfer verification. The company also has a pilot plant for technology transfer and small-scale manufacturing.
Throughout the development process, the team utilizes a full range of small-scale, specialized machinery. Primary equipment in the development suite includes a 25-liter high shear granulator, 16-liter low shear granulator, 12-liter fluid bed with a 6-inch Wurster column, four- to sixteen-liter v-blenders, 10- to 50-liter bins and bin blender, a 10-station rotary press, and impact and rotating...
Norwich, a leader in full-service contract development and manufacturing, today announced the formation of Norwich Clinical Services to provide clinical testing capabilities that will further expand the company’s third party services. Norwich Clinical Services will offer a complete range of clinical research capabilities including Phase I – IV trials, bioanalytical studies and pharmacovigilance monitoring services.
“The introduction of Norwich Clinical Services underscores our strategic focus to provide customers with a comprehensive solution for all stages of product life cycle management,” said Doug Drysdale, chief executive officer of Alvogen, a company that includes Norwich Pharmaceuticals and Norwich Clinical Services. “We have assembled the highest level of professional expertise to ensure Norwich Clinical Services matches our tradition of unparalleled quality standards and delivers contract pharmaceutical services with everyday excellence.”
Dr. Saral Thangam, MD, PhD, managing director of Norwich Clinical Services, will lead an experienced team of professionals who each have at least 15 years experience in clinical research and life sciences. Dr. Thangam completed her medical training with an Internal Medicine specialization at Christian Medical College, Vellore, and her PhD in physiology was earned at St. John...
Norwich Pharmaceuticals, a leader in contract manufacturing and packaging, has recently completed a major capital investment in infrastructure, controls and the specialized equipment necessary to support the pilot scale formulation and Clinical Trial Material (CTM) manufacture of new and existing pharmaceutical products.
The addition of these small-scale services is a major expansion on the part of the New York-based company, which has served the pharmaceutical industry for over 100 years. Prior to this investment in new product formulation, Norwich concentrated its scope of services in commercial-scale manufacturing and packaging. The company’s expansion into new product development required the investment into their pilot-scale equipment and facilities, and signals the aggressiveness with which Norwich is approaching its role in the future of outsourcing services.
In addition to the capital investment in equipment and physical infrastructure, Norwich has been attracting top-level industry executives and project management personnel to advance its role in new product development. Through a selective build-up of personnel and major capital investments Norwich is committed to an increasing its role in the future of biopharmaceutical development as more and more manufacturers seek state-of-the-art, full-service outsourcing...
Norwich Pharmaceuticals, a leader in contract manufacturing and packaging, is now offering comprehensive services toward the development of high-potency compounds. The addition of high potent compound capabilities is the result of a major capital investment and expansion of services on the part of the New York-based company, which has served the pharmaceutical industry for over 100 years. In the past, Norwich has concentrated its efforts on providing contracted services to manufacturing and packaging services.
The company has invested over $3 million in infrastructure, controls and the specialized equipment necessary to support pilot scale Clinical Trial Material (CTM) for the manufacture of high potent compounds, including fast dissolve and controlled release tablets.
The potent compound development facility at Norwich features an HVAC system designed for 20 room air changes per hour, utilizing redundant HEPA filtration to eliminate any possibility of cross-contamination. Separate personnel ingress/egress airlocks, with a separate equipment and materials airlock, provide full containment of compounds. The Norwich facility also has a dedicated control system to monitor and regulate the environmental conditions of every development suite.
The expansion into potent compound development further supports the...
About Norwich
Awards & Recognition
Read about Norwich's CMO Leadership Award designation from Life Science Leader and why "This Company Gets It"
Norwich Capabilities Brochure
Overview Video
Learn more about Norwich.
Interview with Norwich President
Hear the latest from Norwich President, Terry Novak.
